Covid-19 roundup: Re­gen­eron puts its an­ti­bod­ies in­to the clin­ic, rac­ing with Eli Lil­ly for fall au­tho­riza­tion

Re­gen­eron, ar­guably the most-watched de­vel­op­er of a Covid-19 an­ti­body treat­ment, is be­gin­ning clin­i­cal tri­als.

Like oth­er an­ti­body de­vel­op­ers, the big Tar­ry­town, NY biotech will be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER